Decalcification of Breast Cancer Bone Metastases with EDTA Does Not Affect ER, PR, and HER2 Results
- Van Es, S.C. (Suzanne C.)
- Vegt, B. (Bert) van der
- Bensch, F. (Frederike)
- Gerritse, S.L. (Sophie L.)
- Van Helden, E.J. (Erik J.)
- Boon, E. (Eline)
- Angus, L. (Lindsay)
- Overbosch, J. (Jelle)
- Menke-Van Der Houven Van Oordt, C.W. (Catharina W.)
- Verheul, H.M.W. (Henk)
- Herpen, C.M.L. (Carla)
- Jager, A. (Agnes)
- Oosting, S.F. (Sjoukje)
- Vries, E.G.E. (Elisabeth) de
- Schröder, C.P. (Carolina P.)
DOIAbstract
In metastatic breast cancer (MBC), expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) guides treatment selection. In case of bone-only metastatic disease, ER, PR, and HER2 status assessment may be hampered by decalcification. We aimed to determine the optimal decalcification method, and to study discordance of receptor expression between paired primary breast tumors and optimally decalcified bone metastases. First, decalcification was simulated using acetic acid, hydrochloric/formic acid, and EDTA on 12 primary breast carcinomas. ER, PR, and HER2 immunohistochemistry (IHC) and HER2 in situ hybridization (ISH) were assessed, before and after the 3 decalcification methods. EDT...
Add to ORKG